No Data
No Data
A-share midday review: Shanghai Composite Index up 0.38%, with more than 3000 stocks rising. The sectors of vitamins, baijiu and real estate are among the top gainers.
As of the midday close, the Shanghai Composite Index rose 0.38% to 2880.61 points, the Shenzhen Component Index rose 0.49%, and the Chinext Price Index rose 0.09%.
Norinco International Cooperation (000065.SZ) has conducted business negotiations with Hunan Er-Kang Pharmaceutical's Er-Kang Mining on lithium mining.
On July 16, Gelunhui reported that an investor asked Norinco International (000065.SZ) on the investor interaction platform, "Does your company have any business dealings with Hunan Er-Kang Pharmaceutical?" The company responded that in recent years, it has actively developed mining and mining construction business in Nigeria, and has conducted business negotiations on lithium mining with Er-Kang Mining under the umbrella of Hunan Er-Kang Pharmaceutical. At present, no substantive cooperation agreement has been signed.
The Recent Pullback Must Have Dismayed Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) Insiders Who Own 45% of the Company
Investors in Hunan Er-Kang Pharmaceutical (SZSE:300267) From Five Years Ago Are Still Down 54%, Even After 7.5% Gain This Past Week
Erkang Pharmaceutical (300267.SZ): Net profit of 2.9015 million yuan in the first quarter decreased by 88.87% year on year
Gelonghui, April 26 | Erkang Pharmaceutical (300267.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 276 million yuan, down 49.57% year on year; net profit attributable to shareholders of listed companies was 2.9015 million yuan, down 88.87% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 3.3425 million; basic earnings per share.
Erkang Pharmaceutical (300267.SZ) announced first-quarter results, net profit of 2.9015 million yuan, a decrease of 88.87%
According to the Zhitong Finance App, Erkang Pharmaceutical (300267.SZ) released its report for the first quarter of 2024. The company's revenue was 276 million yuan, a year-on-year decrease of 49.57%. Net profit attributable to shareholders of listed companies was 2.9015 million yuan, a year-on-year decrease of 88.87%. The net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was $3.342,500. Basic earnings per share were $0.0014.
No Data